<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13093">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01667107</url>
  </required_header>
  <id_info>
    <org_study_id>5592-105</org_study_id>
    <secondary_id>2012-003140-68</secondary_id>
    <nct_id>NCT01667107</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)</brief_title>
  <acronym>PAPAL</acronym>
  <official_title>A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single site study will examine plasma and alveolar compartment (AC) levels of
      posaconazole in cystic fibrosis (CF) and non-cystic fibrosis (non-CF) lung transplant
      recipients receiving routine post-operative anti-fungal prophylaxis. Invasive fungal
      infection rates will be assessed following transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to an unfavorable risk-benefit analysis
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Time to reach steady state plasma concentration of posaconazole</measure>
    <time_frame>Through Day 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of posaconazole in plasma and alveolar compartment (AC)</measure>
    <time_frame>Through Day 41</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who develop invasive fungal infection</measure>
    <time_frame>Through Week 12 post transplant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Fungal Infection</condition>
  <arm_group>
    <arm_group_label>Posaconazole - CF Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posaconazole will be administered to approximately 20 lung transplant participants with CF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Posaconazole - Non-CF Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posaconazole will be administered to approximately 20 lung transplant participants without CF (non-CF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole</intervention_name>
    <description>Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the patient is unable to meet the conditions for optimal absorption of posaconazole.</description>
    <arm_group_label>Posaconazole - CF Participants</arm_group_label>
    <arm_group_label>Posaconazole - Non-CF Participants</arm_group_label>
    <other_name>SCH056592</other_name>
    <other_name>MK-5592</other_name>
    <other_name>Noxafil®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo lung transplantation

          -  Able to take oral/nasogastric medication

          -  Females of childbearing potential, males, and the sexual partners of males must use
             an effective method of birth control during this study and for 6 weeks after
             completing the study.

        Exclusion Criteria:

          -  Severe liver disease

          -  Current use of cytochrome P-450 (CYP)-3A4 inhibitors including terfenadine,
             astemizole, cisapride, pimozide, halofantrine or quinidine within 7 days before
             transplant

          -  Treatment with posaconazole within 14 days before transplant

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>August 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
